Strides Pharma Q4 Review – U.S., Institutional Business Drives Earnings: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Strides Pharma Science Ltd.’s Q4 FY21 operational performance was marginally below our estimate.

The robust performance in the U.S., institutional segment within emerging markets was offset by subdued sales in other regulated markets on account of Covid-19.

In addition to commercial manufacturing of the Sputnik vaccine by October 2021, the company is building a basket of Covid-related medicines.

The abbreviated new drug application filing momentum is expected to pick-up in FY22, providing growth visibility in the U.S. market.

We cut our FY22E/FY23E earnings estimate by 6% each to account for increased opex associated with logistics and increased price erosion in select products.

Click on the attachment to read the full report:

Motilal Oswal Strides Pharma Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button